Meet the BD&L Team 2019
Hear from our team and find out more about our approach to partnering.
Search
Edda Dankmeyer
Edda Dankmeyer is our Lead of Sustainable Development Communications. She tells us where her passion for sustainability comes from, why she joined us, and how sustainable development can be a key differentiator for the company.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Bees and biodiversity
At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Christian Betz
Prioritizing development with Christian Betz
Anna Mezentseva
Prioritizing development with Anna Mezentseva
Aiko Watabe
Prioritizing development with Aiko Watabe
Knowing the enemy: PRRS and PCVD
The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Dedifferentiated liposarcoma (DDLPS)
An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Uniting to stop rabies: a global and local endeavor
By collaborating together, we can stop rabies. Read how we are breaking down barriers through the power of partnerships to fight this deadly disease
Our Health and Safety initiative - BE SAFE
Health and safety are of great importance to Boehringer Ingelheim.
New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Rare Diseases: Rare but not alone
We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Prawn and Ginger Stir-Fry Video
Learn how to make this well-balanced prawn and ginger stir-fry from Taking Cancer On Through Flavour.
Innovation and drone delivery
Addressing healthcare disparities through collaborative innovation and drone delivery
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Changes in Taste and Smell
Learn about the ways in which you can tackle changes in taste and smell from Taking Cancer On Through Flavour